Antibodies for Cancer Therapy: Exploiting Successful Strategies 2011

More information on Antibodies for Cancer Therapy: Exploiting Successful Strategies

KEYNOTE PRESENTATIONS

Chairperson’s Opening Remarks 8:40 Antibodies for Cancer: Past, Present and Future

Janice Reichert, Ph.D., Research Assistant Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine
The majority of development programs for monoclonal antibodies have focused on cancer, resulting in nearly a dozen marketed products and a variety of novel antibody modalities in clinical study. An overview of development and approval trends for novel anti-cancer mAbs, including bispecific antibodies and antibody-drug conjugates, will be discussed.

Kymouse Platform to Generate Highly Selective, Potent and Well-Tolerated Human Antibody-Based Biopharmaceuticals

Sphingosine-1-Phosphate Antibodies as Potential Agents in the Treatment of Cancer and Age-Related Macular Degeneration